Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease

NCT00032292 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Graft vs Host Disease

Interventions

DRUG: Visilizumab

Sponsor

Facet Biotech